Strides Arcolab
 | |
| MNC (several JVs, and subsidiaries) | |
| Industry | Pharmaceutical |
| Founded | 1990 |
| Headquarters | Bannerghatta Road, Bangalore, India |
Key people |
Arun Kumar (Founder and Group CEO), K R Ravishankar, Deepak Vaidya (Chairman) |
| Products | soft gel, injectables, hard gelatin, solid dosage, sterile parenterals, tablets |
| Revenue |
 $ 566 million (2014)[1] |
Number of employees | approximately 1750 |
| Slogan | Leadership through Partnering |
| Website | www.stridesarco.com |
Strides Arcolab is an Indian pharmaceutical company, headquartered at Bangalore in southern India. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. Its softgel manufacturing capability consists of an annual capacity of 50,000 machine hours or about three billion softgel capsules. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. In the United States and Canadian markets, the company partners with generic companies to supply retail and hospital generics in injectable products and softgels. In European markets, it has long-term relationships for the development of projects and supply agreements with the European companies. In Australia and New Zealand, the company is engaged in manufacturing and supply of soft gels and value-added manufacturing. The company has development and supply agreements with South African companies. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.
Arun Kumar is the founder and Group CEO, and has been on the Board as Managing Directors since its inception. K R Ravishankar is an executive director. Deepak Vaidya was appointed to the board in January, 1998, and was made Chairman of the Board.
Manufacturing
Indian plants
In India the company operates eight pharmaceutical plants:
- KRSG Anekal - The company has three plants at Jigni in the taluka of Anekal in the southern part of the Bangalore metropolitan area. One plant makes soft gelatin capsules, another makes tablets and hard gelatin capsules, and a third makes anti-tuberculosis medicines.
- STAR - Strides Technology & Research - the R&D centre at Bannerghata Road (opp. IIM-B, Bangalore)
On December 5, 2013, the company announced that it had completed the sale of its Agila Specialties Division to Mylan Inc., for a total sum of up to US$1.75 billion.
Non-Indian plants
- Mexico - The company has a plant at Chapultepec.
- Europe - The group owns two companies, one in Italy (Beltapharm S.pA) and the other in Poland (now Strides Polska).
Global Disease Initiative
Strides is in the international market for quality generics to fight HIV/ AIDS, TB and malaria. The company works with the Clinton Foundation to make available a range of lower cost anti-retroviral drugs for the treatment of HIV/AIDS as part of the Clinton Foundation's HIV/AIDS initiative. The company is also on the list of World Health Organization pre-qualified suppliers to supply generic fixed dose combination of anti-HIV drugs. It is an approved supplier to the World Bank, the African Development Bank, PEPFAR President's Emergency Plan For AIDS Relief and UNICEF.